PMID- 34804937
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211123
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or 
      Refractory Peripheral T-Cell Lymphomas in China.
PG  - 750323
LID - 10.3389/fonc.2021.750323 [doi]
LID - 750323
AB  - Chidamide has demonstrated significant clinical benefits for patients with 
      relapsed/refractory (R/R) PTCL in previous studies. This multi-center 
      observational study was aimed to evaluate the objective response rate (ORR), 
      overall survival (OS), and safety of chidamide. From February 2015 to December 
      2017, 548 patients with R/R PTCL from 186 research centers in China were included 
      in the study. Among the 261 patients treated with chidamide monotherapy, ORR was 
      58.6% and 55 patients (21.1%) achieved complete response (CR). Among the 287 
      patients receiving chidamide-containing combination therapies, ORR was 73.2% and 
      73 patients (25.4%) achieved CR. The median OS of all patients was 15.1 months. 
      The median OS of patients receiving chidamide monotherapy and combination 
      therapies was 433 and 463 days, respectively. These results demonstrate a 
      significant survival advantage of chidamide treatments as compared with 
      international historical records. Common adverse effects (AEs) were hematological 
      toxicities. Most AEs in both monotherapy and combined treatments were grade 1-2. 
      No unanticipated AEs occurred. In conclusion, chidamide-based therapy led to a 
      favorable efficacy and survival benefit for R/R PTCL. Future studies should 
      explore the potential advantage of chidamide treatment combined with 
      chemotherapy.
CI  - Copyright (c) 2021 Liu, Zhao, Liu, Niu, Song, Xu, Jin, Cai, Huang, Li, Hou, Zhang, 
      Zhou, Hu, Shen, Shi, Yang, Zhang, Zhao, Ding, Qiu, Tan, Zhang, Liu, Wang, Xu, 
      Zhou, Gao, Xue, Bai, Feng, Huang, Yang, Yan, Zeng, Liu, Li, Mao, Su, Wang, Xu, 
      Zhou, Zhang, Ma, Shen and Zhu.
FAU - Liu, Weiping
AU  - Liu W
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education), Department of Lymphoma, Peking University Cancer Hospital and 
      Institute, Beijing, China.
FAU - Zhao, Donglu
AU  - Zhao D
AD  - Department of Hematology and Oncology, Harbin Institute of Hematology and 
      Oncology, Harbin, China.
FAU - Liu, Ting
AU  - Liu T
AD  - Department of Hematology, West China Hospital Sichuan University, Chengdu, China.
FAU - Niu, Ting
AU  - Niu T
AD  - Department of Hematology, West China Hospital Sichuan University, Chengdu, China.
FAU - Song, Yongping
AU  - Song Y
AD  - Department of Hematology, Henan Cancer Hospital, Zhengzhou, China.
FAU - Xu, Wei
AU  - Xu W
AD  - Department of Hematology, Jiangsu Province Hospital, Nanjing, China.
FAU - Jin, Jie
AU  - Jin J
AD  - Department of Hematology, The First Affiliated Hospital of Zhejiang University, 
      Hangzhou, China.
FAU - Cai, Qingqing
AU  - Cai Q
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      China.
FAU - Huang, Huiqiang
AU  - Huang H
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      China.
FAU - Li, Zhiming
AU  - Li Z
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      China.
FAU - Hou, Ming
AU  - Hou M
AD  - Department of Hematology, Qilu Hospital Shandong University, Jinan, China.
FAU - Zhang, Huilai
AU  - Zhang H
AD  - Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, 
      Tianjin, China.
FAU - Zhou, Jianfeng
AU  - Zhou J
AD  - Department of Hematology, Tongji Hospital Huazhong University of Science and 
      Technology, Wuhan, China.
FAU - Hu, Jianda
AU  - Hu J
AD  - Department of Hematology, The Affiliated Union Hospital of Fujian Medical 
      University, Fuzhou, China.
FAU - Shen, Jianzhen
AU  - Shen J
AD  - Department of Hematology, The Affiliated Union Hospital of Fujian Medical 
      University, Fuzhou, China.
FAU - Shi, Yuankai
AU  - Shi Y
AD  - Department of Medical Oncology, The Cancer Institute and Hospital Chinese Academy 
      of Medical Sciences, Beijing, China.
FAU - Yang, Yu
AU  - Yang Y
AD  - Department of Lymphoma, Fujian Cancer Hospital, Fuzhou, China.
FAU - Zhang, Liling
AU  - Zhang L
AD  - Department of Medical Oncology, Union Hospital Affiliated to Tongji Medical 
      College of Huazhong University of Science and Technology, Wuhan, China.
FAU - Zhao, Weili
AU  - Zhao W
AD  - Department of Hematology, Shanghai Rui Jin Hospital, Shanghai, China.
FAU - Ding, Kaiyang
AU  - Ding K
AD  - Department of Hematology, Anhui Provincial Cancer Hospital, Hefei, China.
FAU - Qiu, Lugui
AU  - Qiu L
AD  - Department of Hematology, The Hematology Institute and Hospital Chinese Academy 
      of Medical Sciences, Tianjin, China.
FAU - Tan, Huo
AU  - Tan H
AD  - Department of Hematology, The First Affiliated Hospital Guangzhou Medical 
      University, Guangzhou, China.
FAU - Zhang, Zhihui
AU  - Zhang Z
AD  - Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China.
FAU - Liu, Lihong
AU  - Liu L
AD  - Department of Hematology, The Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Wang, Jinghua
AU  - Wang J
AD  - Department of Medical Oncology, Nanjing General Hospital of Nanjing Military 
      Command, Nanjing, China.
FAU - Xu, Bing
AU  - Xu B
AD  - Department of Hematology, The First Affiliated Hospital of Xiamen University, 
      Xiamen, China.
FAU - Zhou, Hui
AU  - Zhou H
AD  - Department of Lymphoma, Hunan Cancer Hospital, Changsha, China.
FAU - Gao, Guangxun
AU  - Gao G
AD  - Department of Hematology, Xijing Hospital of Airforce Medical University, Xi'an, 
      China.
FAU - Xue, Hongwei
AU  - Xue H
AD  - Department of Lymphoma, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Bai, Ou
AU  - Bai O
AD  - Department of Hematology, The First Bethune Hospital of Jilin University, 
      Changchun, China.
FAU - Feng, Ru
AU  - Feng R
AD  - Department of Hematology, Nanfang Hospital of Southern Medical University, 
      Guangzhou, China.
FAU - Huang, Xiaobing
AU  - Huang X
AD  - Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan 
      Provincial People's Hospital, Chengdu, China.
FAU - Yang, Haiyan
AU  - Yang H
AD  - Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou, China.
FAU - Yan, Xiaojing
AU  - Yan X
AD  - Department of Hematology, The First Hospital of China Medical University, 
      Shenyang, China.
FAU - Zeng, Qingshu
AU  - Zeng Q
AD  - Department of Hematology, The First Affiliated Hospital of Anhui Medical 
      University, Anhui, China.
FAU - Liu, Peng
AU  - Liu P
AD  - Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, China.
FAU - Li, Wenyu
AU  - Li W
AD  - Department of Lymphoma, Guangdong Provincial People's Hospital, Guangzhou, China.
FAU - Mao, Min
AU  - Mao M
AD  - Department of Hematology, People's Hospital of Xinjiang Uygur Autonomous Region, 
      Urumchi, China.
FAU - Su, Hang
AU  - Su H
AD  - Department of Lymphoma, The Fifth Medical Center of the People's Liberation Army 
      (PLA) General Hospital, Beijing, China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Hematology, Shandong First Medical University Affiliated Provincial 
      Hospital, Jinan, China.
FAU - Xu, Jingyan
AU  - Xu J
AD  - Department of Hematology, Nanjing Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Zhou, Daobin
AU  - Zhou D
AD  - Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
FAU - Zhang, Hongyu
AU  - Zhang H
AD  - Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China.
FAU - Ma, Jun
AU  - Ma J
AD  - Department of Hematology and Oncology, Harbin Institute of Hematology and 
      Oncology, Harbin, China.
FAU - Shen, Zhixiang
AU  - Shen Z
AD  - Department of Hematology, Shanghai Rui Jin Hospital, Shanghai, China.
FAU - Zhu, Jun
AU  - Zhu J
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education), Department of Lymphoma, Peking University Cancer Hospital and 
      Institute, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20211104
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8602952
OTO - NOTNLM
OT  - T-cell
OT  - efficiency
OT  - histone deacetylase inhibitors
OT  - lymphoma
OT  - peripheral
OT  - safety
OT  - survival
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. The reviewer JH declared a shared affiliation, with WZ and 
      a past co-authorship with JJ, TL, LQ, WC, JH, and PL to the handling editor at 
      the time of the review.
EDAT- 2021/11/23 06:00
MHDA- 2021/11/23 06:01
PMCR- 2021/01/01
CRDT- 2021/11/22 06:52
PHST- 2021/07/30 00:00 [received]
PHST- 2021/10/15 00:00 [accepted]
PHST- 2021/11/22 06:52 [entrez]
PHST- 2021/11/23 06:00 [pubmed]
PHST- 2021/11/23 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.750323 [doi]
PST - epublish
SO  - Front Oncol. 2021 Nov 4;11:750323. doi: 10.3389/fonc.2021.750323. eCollection 
      2021.